Intuitive Surgical (NASDAQ:ISRG) PT Raised to $555.00

Intuitive Surgical (NASDAQ:ISRG) had its price objective hoisted by Royal Bank of Canada from $525.00 to $555.00 in a research report released on Friday morning, Marketbeat Ratings reports. The firm currently has an outperform rating on the medical equipment provider’s stock.

ISRG has been the topic of several other research reports. Citigroup raised their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Truist Financial raised their price target on Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Stifel Nicolaus boosted their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Piper Sandler raised their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Finally, Leerink Partners lifted their target price on shares of Intuitive Surgical from $489.00 to $502.00 in a report on Thursday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $513.74.

Intuitive Surgical Stock Up 10.0 %

Shares of ISRG opened at $521.15 on Friday. The company has a market capitalization of $184.85 billion, a price-to-earnings ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical has a 52-week low of $254.85 and a 52-week high of $523.34. The stock has a 50 day moving average price of $483.85 and a 200 day moving average price of $438.56.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the firm posted $1.18 EPS. The company’s revenue was up 14.5% on a year-over-year basis. On average, equities analysts anticipate that Intuitive Surgical will post 5.22 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, insider Mark Brosius sold 2,115 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the transaction, the insider now owns 295 shares in the company, valued at $145,113.45. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the sale, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares of the company’s stock, valued at $402,519.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ISRG. Brown Lisle Cummings Inc. grew its stake in Intuitive Surgical by 17.7% in the 3rd quarter. Brown Lisle Cummings Inc. now owns 1,596 shares of the medical equipment provider’s stock valued at $784,000 after acquiring an additional 240 shares during the last quarter. Godsey & Gibb Inc. lifted its holdings in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares in the last quarter. Vest Financial LLC grew its position in shares of Intuitive Surgical by 202.4% in the third quarter. Vest Financial LLC now owns 2,232 shares of the medical equipment provider’s stock valued at $1,097,000 after purchasing an additional 1,494 shares during the last quarter. Lee Johnson Capital Management LLC purchased a new position in shares of Intuitive Surgical during the 3rd quarter worth approximately $4,018,000. Finally, Cyndeo Wealth Partners LLC increased its stake in shares of Intuitive Surgical by 7.2% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 8,379 shares of the medical equipment provider’s stock worth $4,116,000 after purchasing an additional 564 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.